Erratum: Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape (Clin Invest. (2016) 126:8 (3036–3052) DOI: 10.1172/JCI83416);Tandem CAR T cells targeting HER2 and IL13Rα2 mitigate tumor antigen escape

Journal of Clinical Investigation

Volumn 126, Issue 8, 2016, Pages 3036-3052

  Hegde, Meenakshi ^a,b   Mukherjee, Malini ^b,c   Grada, Zakaria ^a,b   Pignata, Antonella ^a,b   Landi, Daniel ^a,b   Navai, Shoba A ^a,b   Wakefield, Amanda ^a,b   Fousek, Kristen ^a,b   Bielamowicz, Kevin ^a,b   Chow, Kevin K H ^a,b   Brawley, Vita S ^a,b   Byrd, Tiara T ^a,b   Krebs, Simone ^a,b   Gottschalk, Stephen ^a,b   Wels, Winfried S ^d   Baker, Matthew L ^b   Dotti, Gianpietro ^a,b   Mamonkin, Maksim ^a,b   Brenner, Malcolm K ^a,b   Orange, Jordan S ^b,c   Ahmed, Nabil ^a,b   more..

^a CENTER FOR CELL AND GENE THERAPY   (United States)

^b BAYLOR COLLEGE OF MEDICINE   (United States)

^c TEXAS CHILDREN S HOSPITAL   (United States)

^d INSTITUTE FOR TUMOR BIOLOGY AND EXPERIMENTAL THERAPY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CD28 ANTIGEN; CD4 ANTIGEN; CD8 ANTIGEN; CHIMERIC ANTIGEN RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; GAMMA INTERFERON; INTERLEUKIN 13; INTERLEUKIN 13 RECEPTOR ALPHA2; INTERLEUKIN 2; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; TUMOR ANTIGEN; ANTINEOPLASTIC AGENT; ERBB2 PROTEIN, MOUSE; LYMPHOCYTE ANTIGEN RECEPTOR; PROTEIN BINDING;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIGEN RECOGNITION; ARTICLE; CANCER RECURRENCE; CONTROLLED STUDY; CYTOKINE PRODUCTION; CYTOKINE RELEASE; EMBRYO; EX VIVO STUDY; GLIOBLASTOMA; GLIOBLASTOMA CELL LINE; HUMAN; HUMAN CELL; MICROTUBULE ORGANIZING CENTER; MOLECULAR DYNAMICS; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN PROTEIN INTERACTION; PROTEIN TARGETING; RECEPTOR BINDING; T LYMPHOCYTE; T LYMPHOCYTE ACTIVATION; TUMOR XENOGRAFT; UPREGULATION; ADOPTIVE IMMUNOTHERAPY; ANIMAL; BRAIN TUMOR; CANCER TRANSPLANTATION; CHEMISTRY; LYMPHOCYTE ACTIVATION; METABOLISM; PROTEIN MULTIMERIZATION; SCID MOUSE; TRANSGENE; TUMOR CELL LINE; TUMOR ESCAPE; TUMOR RECURRENCE;

ANIMALS; ANTIGENS, NEOPLASM; ANTINEOPLASTIC AGENTS; BRAIN NEOPLASMS; CELL LINE, TUMOR; GLIOBLASTOMA; HUMANS; IMMUNOTHERAPY, ADOPTIVE; INTERLEUKIN-13; INTERLEUKIN-13 RECEPTOR ALPHA2 SUBUNIT; LYMPHOCYTE ACTIVATION; MICE; MICE, SCID; NEOPLASM RECURRENCE, LOCAL; NEOPLASM TRANSPLANTATION; PROTEIN BINDING; PROTEIN MULTIMERIZATION; RECEPTOR, ERBB-2; RECEPTORS, ANTIGEN, T-CELL; T-LYMPHOCYTES; TRANSGENES; TUMOR ESCAPE;

EID: 84987800356     PISSN: 00219738     EISSN: 15588238     Source Type: Journal    
DOI: 10.1172/JCI152477     Document Type: Erratum

References (46)

1. Eshhar Z, Waks T, Gross G, Schindler DG. Specific activation and targeting of cytotoxic lymphocytes through chimeric single chains consisting of antibody-binding domains and the γ or δ subunits of the immunoglobulin and T-cell receptors. Proc Natl Acad Sci U S A. 1993;90(2):720-724.
2. Ahmed N, et al. HER2-specific T cells target primary glioblastoma stem cells and induce regression of autologous experimental tumors. Clin Cancer Res. 2010;16(2):474-485.
3. Krebs S, et al. T cells redirected to interleukin-13Rα2 with interleukin-13 mutein-chimeric antigen receptors have anti-glioma activity but also recognize interleukin-13Rα1. Cytotherapy. 2014;16(8):1121-1131.
4. Chow KK, et al. T cells redirected to EphA2 for the immunotherapy of glioblastoma. Mol Ther. 2013;21(3):629-637.
5. Ahmed N, et al. Immunotherapy for osteosarcoma: genetic modification of T cells overcomes low levels of tumor antigen expression. Mol Ther. 2009;17(10):1779-1787.
6. Rainusso N, et al. Immunotherapy targeting HER2 with genetically modified T cells eliminates tumor-initiating cells in osteosarcoma. Cancer Gene Ther. 2012;19(3):212-217.
7. Rossig C, Bollard CM, Nuchtern JG, Merchant DA, Brenner MK. Targeting of G(D2)-positive tumor cells by human T lymphocytes engineered to express chimeric T-cell receptor genes. Int J Cancer. 2001;94(2):228-236.
8. Ahmed N, et al. Human Epidermal Growth Factor Receptor 2 (HER2)-specific chimeric antigen receptor-modified T cells for the immunotherapy of HER2-positive sarcoma. J Clin Oncol. 2015;33(15):1688-1696.
9. Louis CU, et al. Antitumor activity and longterm fate of chimeric antigen receptor-positive T cells in patients with neuroblastoma. Blood. 2011;118(23):6050-6056.
10. Pule MA, et al. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma. Nat Med. 2008;14(11):1264-1270.
11. Park JR, et al. Adoptive transfer of chimeric antigen receptor re-directed cytolytic T lymphocyte clones in patients with neuroblastoma. Mol Ther. 2007;15(4):825-833.
12. Brentjens RJ, et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med. 2013;5(177):177ra38.
13. Brentjens RJ, et al. Safety and persistence of adoptively transferred autologous CD19-targeted T-cells in patients with relapsed or chemotherapy refractory B-cell leukemias. Blood. 2011;118(18):4817-4828.
14. Grupp SA, et al. Chimeric antigen receptor-modified T-cells for acute lymphoid leukemia. N Engl J Med. 2013;368(16):1509-1518.
15. Kalos M, et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med. 2011;3(95):95ra73.
16. Kochenderfer JN, et al. Eradication of B-lineage cells and regression of lymphoma in a patient treated with autologous T cells genetically engineered to recognize CD19. Blood. 2010;116(20):4099-4102.
17. Porter DL, Levine BL, Kalos M, Bagg A, June CH. Chimeric antigen receptor-modified T-cells in chronic lymphoid leukemia. N Engl J Med. 2011;365(8):725-733.
18. Lee DW, et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: a phase 1 doseescalation trial. Lancet. 2015;385(9967):517-528.
19. Maude SL, et al. Chimeric antigen receptor T-cells for sustained remissions in leukemia. N Engl J Med. 2014;371(16):1507-1517.
20. Hegde M, et al. Combinational targeting offsets antigen escape and enhances effector functions of adoptively transferred T cells in glioblastoma. Mol Ther. 2013;21(11):2087-2101.
21. Zhang JG, et al. Antigenic profiling of glioma cells to generate allogeneic vaccines or dendritic cell-based therapeutics. Clin Cancer Res. 2007;13(2 pt 1):566-575.
22. Liang Y, et al. Gene expression profiling reveals molecularly and clinically distinct subtypes of glioblastoma multiforme. Proc Natl Acad Sci U S A. 2005;102(16):5814-5819.
23. Dunn GP, Old LJ, Schreiber RD. The three Es of cancer immunoediting. Annu Rev Immunol. 2004;22:329-360.
24. Nagaraj S, et al. Altered recognition of antigen is a mechanism of CD8+ T cell tolerance in cancer. Nat Med. 2007;13(7):828-835.
25. Liu G, Ying H, Zeng G, Wheeler CJ, Black KL, Yu JS. HER-2, gp100, and MAGE-1 are expressed in human glioblastoma and recognized by cytotoxic T cells. Cancer Res. 2004;64(14):4980-4986.
26. Jarboe JS, Johnson KR, Choi Y, Lonser RR, Park JK. Expression of interleukin-13 receptor α2 in glioblastoma multiforme: implications for targeted therapies. Cancer Res. 2007;67(17):7983-7986.
27. Wykosky J, Gibo DM, Stanton C, Debinski W. Interleukin-13 receptor α2, EphA2, and Fosrelated antigen 1 as molecular denominators of high-grade astrocytomas and specific targets for combinatorial therapy. Clin Cancer Res. 2008;14(1):199-208.
28. Zhang JG, et al. Tumor antigen precursor protein profiles of adult and pediatric brain tumors identify potential targets for immunotherapy. J Neurooncol. 2008;88(1):65-76.
29. Grada Z, et al. TanCAR: a novel bispecific chimeric antigen receptor for cancer immunotherapy. Mol Ther Nucleic Acids. 2013;2:e105.
30. Kahlon KS, Brown C, Cooper LJ, Raubitschek A, Forman SJ, Jensen MC. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells. Cancer Res. 2004;64(24):9160-9166.
31. Banerjee PP, Orange JS. Quantitative measurement of F-actin accumulation at the NK cell immunological synapse. J Immunol Methods. 2010;355(1-2):1-13.
32. Soderberg O, et al. Direct observation of individual endogenous protein complexes in situ by proximity ligation. Nat Methods. 2006;3(12):995-1000.
33. Hell SW. Microscopy and its focal switch. Nat Methods. 2009;6(1):24-32.
34. Wherry EJ. T-cell exhaustion. Nat Immunol. 2011;12(6):492-499.
35. Maher J, Brentjens RJ, Gunset G, Riviere I, Sadelain M. Human T-lymphocyte cytotoxicity and proliferation directed by a single chimeric TCRδ/ CD28 receptor. Nat Biotechnol. 2002;20(1):70-75.
36. Adusumilli PS, et al. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med. 2014;6(261):261ra151.
37. Duong CP, Westwood JA, Berry LJ, Darcy PK, Kershaw MH. Enhancing the specificity of T-cell cultures for adoptive immunotherapy of cancer. Immunotherapy. 2011;3(1):33-48.
38. Wilkie S, et al. Dual targeting of ErbB2 and MUC1 in breast cancer using chimeric antigen receptors engineered to provide complementary signaling. J Clin Immunol. 2012;32(5):1059-1070.
39. Hacein-Bey-Abina S, et al. Insertional oncogenesis in 4 patients after retrovirus-mediated gene therapy of SCID-X1. J Clin Invest. 2008;118(9):3132-3142.
40. Craft AW, et al. A pilot study of screening for neuroblastoma in the north of England. Am J Pediatr Hematol Oncol. 1992;14(4):337-341.
41. Wels W, Harwerth IM, Zwickl M, Hardman N, Groner B, Hynes NE. Construction, bacterial expression and characterization of a bifunctional single-chain antibody-phosphatase fusion protein targeted to the human erbB-2 receptor. Biotechnology (NY). 1992;10(10):1128-1132.
42. Raab D, Graf M, Notka F, Schodl T, Wagner R. The GeneOptimizer Algorithm: using a sliding window approach to cope with the vast sequence space in multiparameter DNA sequence optimization. Syst Synth Biol. 2010;4(3):215-225.
43. Riviere I, Brose K, Mulligan RC. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc Natl Acad Sci U S A. 1995;92(15):6733-6737.
44. Ahmed N, et al. Regression of experimental medulloblastoma following transfer of HER2-specific T cells. Cancer Res. 2007;67(12):5957-5964.
45. Yvon E, et al. Immunotherapy of metastatic melanoma using genetically engineered GD2-specific T cells. Clin Cancer Res. 2009;15(18):5852-5860.
46. Gottschalk S, et al. Generating CTLs against the subdominant Epstein-Barr virus LMP1 antigen for the adoptive immunotherapy of EBV-associated malignancies. Blood. 2003;101(5):1905-1912.